Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

被引：116

作者：

Santra, S

Seaman, MS

Xu, L

Barouch, DH

Lord, CI

Lifton, MA

Gorgone, DA

Beaudry, KR

Svehla, K

Welcher, B

Chakrabarti, BK

Huang, Y

Yang, ZY

Mascola, JR

Nabel, GJ

Letvin, NL

机构：

[1] Harvard Univ, Sch Med, Dept Med,Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02215 USA

[2] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA

来源：

JOURNAL OF VIROLOGY | 2005年 / 79卷 / 10期

关键词：

D O I：

10.1128/JVI.79.10.6516-6522.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The magnitude and durability of immune responses induced by replication-defective adenovirus serotype 5 (ADV5) vector-based vaccines were evaluated in the simian-human immunodeficiency virus/rhesus monkey model. A single inoculation of recombinant ADV5 vector constructs induced cellular and humoral immunity, but the rapid generation of neutralizing anti-Ad5 antibodies limited the immunity induced by repeated vector administration. The magnitude and durability of the immune responses elicited by these vaccines were greater when they were delivered as boosting immunogens in plasmid DNA-primed monkeys than when they were used as single-modality immunogens. Therefore, administration of ADV5-based vectors in DNA-primed subjects may be a preferred use of this vaccine modality for generating long-term immune protection.

引用

页码：6516 / 6522

页数：7

共 18 条

[1]

AMARA RR, 2001, MVA VACCINE, V292, P69

[2] Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity [J].

Barouch, DH ;

Pau, MG ;

Custers, JHHV ;

Koudstaal, W ;

Kostense, S ;

Havenga, MJE ;

Truitt, DM ;

Sumida, SM ;

Kishko, MG ;

Arthur, JC ;

Korioth-Schmitz, B ;

Newberg, MH ;

Gorgone, DA ;

Lifton, MA ;

Panicali, DL ;

Nabel, GJ ;

Letvin, NL ;

Goudsmit, J .

JOURNAL OF IMMUNOLOGY, 2004, 172 (10) :6290-6297

[3] Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines [J].

Barouch, DH ;

McKay, PF ;

Sumida, SM ;

Santra, S ;

Jackson, SS ;

Gorgone, DA ;

Lifton, MA ;

Chakrabarti, BK ;

Xu, L ;

Nabel, GJ ;

Letvin, NL .

JOURNAL OF VIROLOGY, 2003, 77 (16) :8729-8735

[4] Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].

Barouch, DH ;

Santra, S ;

Schmitz, JE ;

Kuroda, MJ ;

Fu, TM ;

Wagner, W ;

Bilska, M ;

Craiu, A ;

Zheng, XX ;

Krivulka, GR ;

Beaudry, K ;

Lifton, MA ;

Nickerson, CE ;

Trigona, WL ;

Punt, K ;

Freed, DC ;

Guan, LM ;

Dubey, S ;

Casimiro, D ;

Simon, A ;

Davies, ME ;

Chastain, M ;

Strom, TB ;

Gelman, RS ;

Montefiori, DC ;

Lewis, MG ;

Emini, EA ;

Shiver, JW ;

Letvin, NL .

SCIENCE, 2000, 290 (5491) :486-492

[5] Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene [J].

Casimiro, DR ;

Chen, L ;

Fu, TM ;

Evans, RK ;

Caulfield, MJ ;

Davies, ME ;

Tang, A ;

Chen, MC ;

Huang, LY ;

Harris, V ;

Freed, DC ;

Wilson, KA ;

Dubey, S ;

Zhu, DM ;

Nawrocki, D ;

Mach, H ;

Troutman, R ;

Isopi, L ;

Williams, D ;

Hurni, W ;

Xu, Z ;

Smith, JG ;

Wang, S ;

Liu, X ;

Guan, LM ;

Long, R ;

Trigona, W ;

Heidecker, GJ ;

Perry, HC ;

Persaud, N ;

Toner, TJ ;

Su, Q ;

Liang, XP ;

Youil, R ;

Chastain, M ;

Bell, AJ ;

Volkin, DB ;

Emini, EA ;

Shiver, JW .

JOURNAL OF VIROLOGY, 2003, 77 (11) :6305-6313

[6] Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization [J].

Chakrabarti, BK ;

Kong, W ;

Wu, B ;

Yang, ZY ;

Friborg, J ;

Ling, X ;

King, SR ;

Montefiori, DC ;

Nabel, GJ .

JOURNAL OF VIROLOGY, 2002, 76 (11) :5357-5368

[7] Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection [J].

Egan, MA ;

Charini, WA ;

Kuroda, MJ ;

Schmitz, JE ;

Racz, P ;

Tenner-Racz, K ;

Manson, K ;

Wyand, M ;

Lifton, MA ;

Nickerson, CE ;

Fu, TM ;

Shiver, JW ;

Letvin, NL .

JOURNAL OF VIROLOGY, 2000, 74 (16) :7485-7495

[8] Use of major histocompatibility complex class I/peptide/β2M tetramers to quantitate CD8+ cytotoxic T lymphocytes specific for dominant and nondominant viral epitopes in simian-human immunodeficiency virus-infected rhesus monkeys [J].

Egan, MA ;

Kuroda, MJ ;

Schmitz, JE ;

Charini, WA ;

Lord, CI ;

Forman, MA ;

Letvin, NL .

JOURNAL OF VIROLOGY, 1999, 73 (07) :5466-5472

[9] Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara [J].

Hirsch, VM ;

Fuerst, TR ;

Sutter, G ;

Carroll, MW ;

Yang, LC ;

Goldstein, S ;

Piatak, M ;

Elkins, WR ;

Alvord, WG ;

Montefiori, DC ;

Moss, B ;

Lifson, JD .

JOURNAL OF VIROLOGY, 1996, 70 (06) :3741-3752

[10] Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression [J].

Huang, Y ;

Kong, WP ;

Nabel, GJ .

JOURNAL OF VIROLOGY, 2001, 75 (10) :4947-4951

← 1 2 →